AI Article Synopsis
- The treatment for advanced thyroid cancer usually involves surgery followed by a type of therapy called radioiodine, but using another treatment called EBRT (external beam radiotherapy) is still being discussed.
- A group of experts looked into whether adding EBRT to the standard treatment helps patients more without causing too many side effects.
- They found that adding EBRT helped control the cancer better and didn't cause significant harm, but they are still unsure if it's the best option, so they recommend considering both treatments together or just using radioiodine alone.
Article Abstract
Background: Treatment for locally advanced differentiated thyroid cancer is surgery followed by radioiodine while the role of adjuvant external beam radiotherapy (EBRT) is debated.
Methods: The panel of the Italian Association of Radiotherapy and Clinical Oncology developed a clinical recommendation on the addition of EBRT to radioiodine after surgery for locally advanced differentiated thyroid cancer by using the Grades of Recommendation, Assessment, Development, and Evaluation methodology and the Evidence to Decision framework. A systematic review with meta-analysis about this topic was conducted with a focus on outcome of benefits and toxicity.
Results: Locoregional control was improved by EBRT while no considerable toxicity impact was reported.
Conclusion: The panel judged uncertain the benefit/harms balance; final recommendation was conditional both for EBRT + radioiodine and radioiodine alone in the adjuvant setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0300891621996817 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!